Tolerogenic peptides from myelin basic protein
CA 2473469 C · Owner: Mazza, Graziella · Inventors: Streeter, Heather Barbara; Mazza, Graziella; Wraith, David Cameron
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
There is provided a peptide which is capable of binding to an MHC class I or II molecule without further processing (i.e. an apitope) which comprises a portion of the region (131-158) of myelin basic protein in particular there , is provided an apitope which is selected from the following myelin basic protein peptides: (134-148, 135-149, 136-150 137-151, 138-152, 139-153, 140-, 154). There is also provided the use of such a peptide in a pharmaceutical composition and a method to treat and/or prevent a disease using such a peptide.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 30, 2003 and granted April 24, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 30, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 30, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.